Elliott Gruskin is a global pharmaceutical operating executive with expertise in transforming innovative research concepts into commercial opportunities. Most recently, he served as Executive Director, Research, Strategy & Innovation at Mallinckrodt Pharmaceuticals. Prior to joining Mallinckrodt, Dr. Gruskin spent more than a decade with DePuy Synthes in the Biomaterials Division, as Global Vice President of R&D and then Worldwide President. In that role, he led an organization with over 200 employees with R&D and manufacturing sites in the US and Switzerland. During his tenure, the Biomaterials portfolio enjoyed double digit growth with $350 M in topline sales. Following the acquisition of Synthes by J&J in 2012, he became Worldwide President of DePuy Synthes Biomaterials before being appointed Global Lead for External Innovation and Enabling Technologies in Biomaterials. Dr. Gruskin received a BS in Biochemistry with High Distinction in Research from the University of Rochester and a PhD in Biochemistry from Vanderbilt University where he was a Chemical Industry Institute of Toxicology Predoctoral Fellow and a Harold Sterling Vanderbilt Scholar. He completed Post-doctoral training in the Department of Biology at the Massachusetts Institute of Technology. He began his pharmaceutical career with United State Surgical Corporation (now Covidien).